Shots:

• The approval is based on two P-III studies POLARIS-1 and POLARIS-4 assessing Vosevi in patients with HCV genotype 1-6 with or without compensated cirrhosis who had failed prior DAA treatment with or without an NS5A inhibitor
• The study resulted in 97% of patients achieved 1EP @SVR12 to determine cure rate- defined as HCV RNA undetectable 12 weeks after completing therapy
• Vosevi is a combination of (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) administered once daily and has a boxed warning of the risk of Hepatitis B virus reactivation in HCV/HBV coinfected- also received the US FDA’s and EMA’s marketing approval in 2017

Click here to read full press release/ article

Ref: Gilead | Image: Gilead